View in EDS HTML Full Text PDF Full Text

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.

Saved in:
Bibliographic Details
Title: Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.
Authors: Wang, Xinyue1 (AUTHOR), Li, Zhaona2 (AUTHOR), Wang, Liuchun1 (AUTHOR), Liang, Yan1 (AUTHOR), Huang, Chun1 (AUTHOR), Chen, Peng1 (AUTHOR), Huang, Dingzhi1 (AUTHOR), Song, Xia3 (AUTHOR), Ding, Cuimin4 (AUTHOR) wjwdcm@sina.com, Wang, Changli5 (AUTHOR) wangchangli@tjmuch.com, Jiang, Richeng1,6 (AUTHOR) jiangricheng@tjmuch.com
Source: BMC Medicine. 4/15/2025, Vol. 23 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17417015
DOI:10.1186/s12916-025-04044-8